What's Happening?
Hexiris Ophthalmics, a Canadian ophthalmic device company, has announced significant progress in its mission to expand access to interventional glaucoma care. The company is preparing for the commercial launch of its first products later in 2026, which
include the OBi Core and OBi Gon devices. These devices are designed for minimally invasive glaucoma surgeries that can be performed in office settings, potentially increasing accessibility for patients. Hexiris has also launched a digital presence, including a new website and social media channels, to engage with surgeons and stakeholders. The company will participate in the Canadian Ophthalmological Society Annual Meeting in Montreal, where surgeons can experience the devices firsthand through a hands-on dry lab.
Why It's Important?
The development of office-based surgical devices for glaucoma is significant as it addresses a major barrier in glaucoma treatment: access to care. Traditional glaucoma surgeries are often confined to operating rooms, limiting patient access. By enabling procedures in office settings, Hexiris Ophthalmics' technologies could reduce costs and increase the availability of treatment, particularly in areas where access to surgical facilities is limited. This shift could lead to earlier interventions and better outcomes for patients, potentially reducing the number of untreated glaucoma cases, which is currently high worldwide.
What's Next?
Hexiris Ophthalmics plans to continue its engagement with the ophthalmic community through its digital platforms and upcoming events. The company is focused on the commercial launch of its products and expanding its reach to more surgeons and patients. The participation in the Canadian Ophthalmological Society Annual Meeting will be a key opportunity for Hexiris to demonstrate its technologies and gather feedback from the medical community. As the company moves forward, it will likely focus on regulatory approvals and expanding its market presence.
